Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease
- 1 January 2003
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (7) , 1141-1146
- https://doi.org/10.1080/1042819031000079096
Abstract
During the past 5 years, better understanding of immunomodulatory and anti-angiogenesis properties of thalidomide has increased interest in the use of this agent for a wider variety of clinical applications. This article reviews the clinical evaluation of thalidomide for treatment or prevention of chronic graft-versus-host-disease.Keywords
This publication has 26 references indexed in Scilit:
- Response to thalidomide therapy in refractory chronic graft-versus-host diseaseBone Marrow Transplantation, 2000
- The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in childrenBone Marrow Transplantation, 1998
- Thalidomide as replacement for steroids in immunosuppression after lung transplantationThe Annals of Thoracic Surgery, 1995
- Thalidomide for the Treatment of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1992
- Thalidomide treatment for chronic graft‐versus‐host diseaseBritish Journal of Haematology, 1991
- The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory informationLeukemia Research, 1990
- TREATMENT AND PREVENTION OF ACUTE GRAFT-VERSUSHOST DISEASE WITH THALIDOMIDE IN A RAT MODELTransplantation, 1986
- Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditionsJournal of the American Academy of Dermatology, 1982
- Effect of Thalidomide on the Graft versus Host ReactionNature, 1966
- IMMUNOSUPPRESSION BY THALIDOMIDE: IMPLICATIONS FOR TERATOLOGYThe Lancet, 1966